WO2002004007A3 - Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof - Google Patents

Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof Download PDF

Info

Publication number
WO2002004007A3
WO2002004007A3 PCT/US2001/018701 US0118701W WO0204007A3 WO 2002004007 A3 WO2002004007 A3 WO 2002004007A3 US 0118701 W US0118701 W US 0118701W WO 0204007 A3 WO0204007 A3 WO 0204007A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
fixed
viral capsid
stable
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/018701
Other languages
French (fr)
Other versions
WO2002004007A9 (en
WO2002004007A2 (en
Inventor
C Richard Schlegel
Robert Garcea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Priority to AU2001275438A priority Critical patent/AU2001275438A1/en
Priority to US10/332,037 priority patent/US7279306B2/en
Priority to EP01942147A priority patent/EP1305039B1/en
Priority to DE60137230T priority patent/DE60137230D1/en
Publication of WO2002004007A2 publication Critical patent/WO2002004007A2/en
Publication of WO2002004007A3 publication Critical patent/WO2002004007A3/en
Publication of WO2002004007A9 publication Critical patent/WO2002004007A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Novel acetone- or alcohol-fixed viral capsid proteins, bacteria-containing, and papillomavirus L1-GST fusion proteins are described. These proteins are useful in vaccine preparation and as diagnostics.
PCT/US2001/018701 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof Ceased WO2002004007A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001275438A AU2001275438A1 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
US10/332,037 US7279306B2 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
EP01942147A EP1305039B1 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
DE60137230T DE60137230D1 (en) 2000-07-06 2001-06-11 STABLE (FIXED) FORMS OF VIRAL L1 CAPSID PROTEINS, THEIR FUSION PROTEINS, AND THEIR USES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21652600P 2000-07-06 2000-07-06
US60/216,526 2000-07-06

Publications (3)

Publication Number Publication Date
WO2002004007A2 WO2002004007A2 (en) 2002-01-17
WO2002004007A3 true WO2002004007A3 (en) 2002-04-18
WO2002004007A9 WO2002004007A9 (en) 2002-10-10

Family

ID=22807390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018701 Ceased WO2002004007A2 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Country Status (7)

Country Link
US (1) US7279306B2 (en)
EP (1) EP1305039B1 (en)
AT (1) ATE418997T1 (en)
AU (1) AU2001275438A1 (en)
DE (1) DE60137230D1 (en)
ES (1) ES2317910T3 (en)
WO (1) WO2002004007A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MXPA05000287A (en) 2002-07-05 2005-09-08 Leclerc Denis Adjuvant viral particle.
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
ATE519451T1 (en) 2004-08-30 2011-08-15 Neville Alleyne IMPLANT FOR THE TREATMENT OF LIGAMENTS AND TENDONS
WO2006026731A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AT503690A1 (en) 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
WO2008058369A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US8469961B2 (en) 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010045431A2 (en) * 2008-10-17 2010-04-22 The Regents Of The University Of Colorado, A Body Corporate Dry powder formulations, vaccines and methods
CN102449479B (en) 2009-05-07 2015-11-25 安科健康公司 Identify high-grade or ≥CIN2 for early and late detection, screening and diagnosis of human papillomavirus (HPV) and HPV-related cancers
JP5819851B2 (en) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Cell-based high-throughput HPV immunoassay for the treatment and screening of HPV-related cancers
CN111000991B (en) * 2019-12-20 2023-04-21 浙江普康生物技术股份有限公司 Coxsackie virus A group 6 recombinant subunit protein vaccine and preparation method thereof
CN112472821B (en) * 2020-11-19 2022-11-18 北京大学 Application of protein nanoparticles in preparation of VSV (VSV virus) resistant product

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
WO1996011272A2 (en) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papilloma virus-like particles, fusion proteins and process for producing the same
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
WO2000050447A1 (en) * 1999-02-24 2000-08-31 Acorda Therapeutics Carbohydrate epitope mimic peptides and uses thereof
DE19925199A1 (en) * 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5475099A (en) * 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
CA2302545C (en) * 1997-09-05 2012-04-03 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
WO1996011272A2 (en) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papilloma virus-like particles, fusion proteins and process for producing the same
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
WO2000050447A1 (en) * 1999-02-24 2000-08-31 Acorda Therapeutics Carbohydrate epitope mimic peptides and uses thereof
DE19925199A1 (en) * 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN XIAOJIANG S ET AL: "Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1.", JOURNAL OF MOLECULAR BIOLOGY, vol. 307, no. 1, 2001, pages 173 - 182, XP001051085, ISSN: 0022-2836 *
NELSON LISA M ET AL: "Nuclear import and DNA binding of human papillomavirus type 45 L1 capsid protein.", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 79, no. 2, 1 November 2000 (2000-11-01), pages 225 - 238, XP001051086, ISSN: 0730-2312 *
SEHR P ET AL: "A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 253, no. 1-2, 1 July 2001 (2001-07-01), pages 153 - 162, XP004241368, ISSN: 0022-1759 *
SMITH D B ET AL: "SINGLE-STEP PURIFICATION OF POLYPEPTIDES EXPRESSED IN ESCHERICHIA COLI AS FUSIONS WITH GLUTATHIONE S-TRANSFERASE", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 67, no. 1, 1988, pages 31 - 40, XP002033198, ISSN: 0378-1119 *
YUAN HANG ET AL: "Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.", JOURNAL OF VIROLOGY, vol. 75, no. 17, September 2001 (2001-09-01), pages 7848 - 7853, XP001053091, ISSN: 0022-538X *
ZHOU J ET AL: "DEFINITION OF LINEAR ANTIGENIC REGIONS OF THE HPV16L1 CAPSID PROTEIN USING SYNTHETIC VIRION-LIKE PARTICLES", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 189, no. 2, 1992, pages 592 - 599, XP000882827, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2002004007A9 (en) 2002-10-10
US20070212374A1 (en) 2007-09-13
DE60137230D1 (en) 2009-02-12
EP1305039A2 (en) 2003-05-02
ATE418997T1 (en) 2009-01-15
WO2002004007A2 (en) 2002-01-17
ES2317910T3 (en) 2009-05-01
EP1305039B1 (en) 2008-12-31
AU2001275438A1 (en) 2002-01-21
US7279306B2 (en) 2007-10-09

Similar Documents

Publication Publication Date Title
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
WO1999033868A3 (en) Human papillomavirus vaccine
EP0757717A4 (en) PAPILLOMAVIRUS VACCINES
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
PT1292328E (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
WO1999010375A3 (en) Vaccine against hpv
PT1526172E (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
CA2366072A1 (en) Prrsv vaccines
MXPA02007478A (en) Human immunodeficiency virus vaccine.
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
AU2001241418A1 (en) Nucleic acids, proteins, and antibodies
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
WO2002038792A3 (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
ATE267256T1 (en) HEPATIS E VIRUS ANTIGENS AND THEIR USES
TW200502245A (en) Vaccine
WO2001060838A3 (en) Aids ancestral viruses and vaccines
AU5608798A (en) Formulations of recombinant papillomavirus vaccines
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
EP1310552A3 (en) Posh nucleic acids, polypeptides and related methods
AU2003300870A1 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
PT1165797E (en) Particles for gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10332037

Country of ref document: US

Ref document number: 2007212374

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001942147

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001942147

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 10332037

Country of ref document: US